REVIEW article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1691719
This article is part of the Research TopicCancer Immunity: From Immunosurveillance to Immune Escape and Therapeutic TargetingView all articles
Rewiring Tumor Visibility: The Immunopeptidome as a Dynamic Interface Between Antigen Processing, Microenvironmental Stress, and Immune Recognition
Provisionally accepted
- Jilin Province Tumor Hospital, Changchun, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The tumor immunopeptidome dictates whether malignant cells remain visible or invisible to immune surveillance, yet its regulation extends far beyond canonical antigen processing. Here, we synthesize recent insights into how proteasomes, immunoproteasomes, transporter associated with antigen processing (TAP), endoplasmic reticulum aminopeptidase (ERAP), and alternative pathways collectively shape peptide presentation, and how tumor-intrinsic rewiring intersects with microenvironmental stressors such as hypoxia, acidity, and epithelial–mesenchymal transition (EMT). We highlight post-translationally modified ligands as a qualitatively distinct class of tumor antigens, expanding the therapeutic landscape. Across various cancers, the immunoproteasome emerges as both a biomarker and a barometer, with prognostic and predictive value contingent upon the immune context. This duality highlights the necessity for context-aware therapeutic strategies, encompassing selective immunoproteasome modulation, TAP2-based biomarkers, and post-translational modification (PTM)-directed vaccines. Framing the immunopeptidome as a dynamic and rewritable interface provides both mechanistic insight into immune escape and a roadmap for precision immuno-oncology.
Keywords: Tumor immunopeptidome, antigen processing, immunoproteasome, post-translational modifications, immunotherapy biomarkers
Received: 24 Aug 2025; Accepted: 21 Oct 2025.
Copyright: © 2025 QI, Zhao, Huang, Chang, Wang and Ye. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jinhong QI, qijinhong2003@sina.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.